




When to initiate dual antiplatelet therapy using cilostazol for secondary prevention in high-risk ischemic stroke: CSPS.com

✓ Multicenter, randomized, open-label, parallel-group

Main results: Toyoda K, et al. Lancet Neurol 2019;18:539-548







Kaplan-Meier analysis for recurrence of ischemic stroke

aHR 0.34 (95% CI 0.12 – 0.95)


aHR 0.27 (95% CI 0.12 – 0.63)



No. at risk		0	200	400	600	800	1000	1200
Mono	Dual	258	204	149	97	61	36	15
		240	168	130	89	61	37	15




No. at risk		0	200	400	600	800	1000	1200
Mono	Dual	238	186	134	88	51	17	7
		229	172	132	92	63	32	13



No. at risk		0	200	400	600	800	1000	1200
Mono	Dual	451	367	283	206	126	55	21
		463	341	275	187	112	45	16



Seamless DAPT strategy for secondary stroke prevention



Good timing for changing from ASA+CLO to CLZ+ASA/CLZ+CLO